Collaboration greatly reduces cost and administrative burden in clinical research.
HealthCarePoint (HCP) and ViS Research today announced they will connect platforms to improve cost-efficiency in clinical research. The partnership will allow clinical trial planners to quickly access clinical research professionals’ Personal Experience and Training (PET) records through the ViS platform and give clinical research sites access to human resource management systems hosted by HealthCarePoint at no cost.
Sites and clinical researchers benefit from an efficient way to share their qualifications, while trial planners gain ready access to structured data for compliance and site evaluation for inclusion in trials. The number of healthcare professionals that are already holding their qualification records through HealthCarePoint's network is close to 500,000, so it is clear that the impact will be substantial.
Users of ViS' online feasibility platform, which include most large pharma companies and CROs, will have seamless and quick access to the information they need for site feasibility assessment. The functional integration of these two innovative technologies will provide a complete solution to industry sponsors, CROs, IRB representatives, and research associations who need to search, find, retrieve and maintain verifiable information on professional competencies for regulatory compliance purposes.
The collaboration aims to revamp an outdated process, which is still based on questionnaires and numerous silos of stale information. On the one hand, it eliminates the need for the cumbersome feasibility questionnaires. On the other, it allows professionals to share their portable PET records, across the industry. The end result is that the time spent conducting feasibility assessment and building records drops to hours, instead of months, and researchers save billions per year in time and resources.
“HealthcarePoint’s and ViS’ patent-pending technologies are complementary and have been proven to be a catalyst for cost-efficiency in this industry,” says Al O.Pacino, HealthCarePoint President. "Empowering researchers to exchange and dynamically share information in real time through permission-based networks will improve efficiency, compliance and competitiveness. The rapid adoption we are seeing indicates that our industry is ready to move beyond ‘silo’ models and into global collaborative environments".
"Society wins when medical researchers focus less on paperwork and more on patients," says Fabio Thiers, MD, PhD, ViS Research CEO. “This collaboration revamps the site feasibility assessment process. Trial planners have had to resort to creating burdensome questionnaires for researchers, because they do not have an efficient way to access and make sense of the information about locations, sites and investigators. Now they have a better option".
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.